Combined polymerase chain reaction methods to detect c-myc/IgH rearrangement in childhood Burkitt's lymphoma for minimal residual disease analysis

Haematologica

Volumn 89, Issue 7, 2004, Pages 818-825

  Busch, Kerstin ^a   Borkhardt, Arndt ^b   Wößmann, Wilhelm ^a   Reiter, Alfred ^a   Harbott, Jochen ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Burkitt's lymphoma; C myc IgH translocation; MRD; PCR

Indexed keywords

GENOMIC DNA; IMMUNOGLOBULIN HEAVY CHAIN;

ADOLESCENT; ARTICLE; BLOOD; BONE MARROW; BURKITT LYMPHOMA; CANCER CELL CULTURE; CHILD; CHILDHOOD CANCER; CHROMOSOME 14Q; CHROMOSOME 8Q; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DILUTION; FEMALE; GENE REARRANGEMENT; GENETIC VARIABILITY; GENOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; PATIENT MONITORING; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS;

ADOLESCENT; BURKITT LYMPHOMA; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 8; DNA PRIMERS; FEMALE; GENES, IMMUNOGLOBULIN; GENES, MYC; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; MALE; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; TRANSLOCATION, GENETIC;

EID: 3242774615     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Reiter A, Schrappe M, Parwaresch R, Henze G, Muller-Weihrich S, Sauter S, et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage-a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol 1995;13:359-72.
2. Sandlund JT, Downing JR, Crist WM. Non-Hodgkin's lymphoma in childhood. N Engl J Med 1996;334:1238-48.
3. Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, Zimmermann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 1999;94:3294-306.
4. Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D, et al. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001;97:3370-9.
5. Philip T, Hartmann O, Pinkerton R, Zucker JM, Gentet JC, Lamagnere JP, et al. Curability of relapsed childhood B-cell non-Hodgkin's lymphoma after intensive first line therapy: a report from the Societe Francaise d'Oncologie Pediatrique. Blood 1993;81:2003-6.
6. Cairo MS, Sposto R, Perkins SL, Meadows AT, Hoover-Regan ML, Anderson JR, et al. Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group Experience. Br J Haematol 2003;120:660-70.
7. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998;352:1731-8.
8. Biondi A, Valsecchi MG, Seriu T, D'Aniello E, Willemse MJ, Fasching K, et al. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Leukemia 2000;14:1939-43.
9. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000;96:2691-6.
10. Drexler HG, MacLeod RA, Borkhardt A, Janssen JW. Recurrent chromosomal translocations and fusion genes in leukemia-lymphoma cell lines. Leukemia 1995;9:480-500.
11. Dworzak MN, Froschl G, Printz D, Mann G, Potschger U, Muhlegger N, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002;99:1952-8.
12. Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol 2003;121:823-38.
13. Emanuel BS, Selden JR, Chaganti RS, Jhanwar S, Nowell PC, Croce CM. The 2p breakpoint of a 2;8 translocation in Burkitt lymphoma interrupts the V kappa locus. Proc Natl Acad Sci USA 1984;81:2444-6.
14. Hollis GF, Mitchell KF, Battey J, Potter H, Taub R, Lenoir GM, et al. A variant translocation places the λ immunoglobulin genes 3′ to the c-myc oncogene in Burkitt's lymphoma. Nature 1984;307:752-5.
15. Neri A, Barriga F, Knowles DM, Magrath IT, Dalla-Favera R. Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. Proc Natl Acad Sci USA 1988;85:2748-52.
16. Dalla-Favera R, Martinotti S, Gallo RC, Erikson J, Croce CM. Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas. Science 1983;219:963-7.
17. Shiramizu B, Magrath I. Localization of breakpoints by polymerase chain reactions in Burkitt's lymphoma with 8;14 translocations. Blood 1990;75:1848-52.
18. Akasaka T, Muramatsu M, Ohno H, Miura I, Tatsumi E, Fukuhara S, et al. Application of long-distance polymerase chain reaction to detection of junctional sequences created by chromosomal translocation in mature B-cell neoplasms. Blood 1996;88:985-94.
19. zur Stadt U, Hoser G, Reiter A, Welte K, Sykora KW. Application of long PCR to detect t(8;14)(q24;q32) translocations in childhood Burkitt's lymphoma and B-ALL. Ann Oncol 1997;8 Suppl 1:31-5.
20. Basso K, Frascella E, Zanesco L, Rosolen A. Improved long-distance polymerase chain reaction for the detection of t(8;14) (q24;q32) in Burkitt's lymphomas. Am J Pathol 1999;155:1479-85.
21. Mussolin L, Basso K, Pillon M, D'Amore ES, Lombardi A, Luzzatto L, et al. Prospective analysis of minimal bone marrow infiltration in pediatric Burkitt's lymphomas by long-distance polymerase chain reaction for t(8;14)(q24;q32). Leukemia 2003;17:585-9.
22. Showe LC, Ballantine M, Nishikura K, Erikson J, Kaji H, Croce CM. Cloning and sequencing of a c-myc oncogene in a Burkitt's lymphoma cell line that is translocated to a germ line α switch region. Mol Cell Biol 1985;5:501-9.
23. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 1980;7:332-9.
24. zur Stadt U, Hoser G, Reiter A, Welte K, Sykora KW. Application of long PCR to detect t(8;14)(q24;q32) translocations in childhood Burkitt's lymphoma and B-ALL. Ann Oncol 1997;8 Suppl 1:31-5.
25. Cario G, Stadt UZ, Reiter A, Welte K, Sykora KW. Variant translocations in sporadic Burkitt's lymphoma detected in fresh tumour material: analysis of three cases. Br J Haematol 2000;110:537-46.
26. Summers KE, Davies AJ, Matthews J, Jenner MJ, Cornelius V, Amess A et al. The relative role of peripheral blood and bone marrow for monitoring molecular evidence of disease in follicular lymphoma by quantitative real-time polymerase chain reaction. Br J Haematol 2002;118:563-6.
27. Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002;99:856-62.
28. Hirt C, Schuler F, Dolken G. Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab. Semin Cancer Biol 2003;13:223-31.
29. Novella E, Giaretta I, Elice F, Madeo D, Piccin A, Castaman G, et al. Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma. Haematologica 2002;87:1157-64.
30. Togel F, Kroger N, Korioth F, Fehse B, Zander AR, Molecular methods for detection and quantification of myeloma cells after bone marrow transplantation: comparison between real-time quantitative and nested PCR. J Hematother Stem Cell Res 2002;11:971-6.
31. Fenk R, Haas R, Kronenwett R. Molecular monitoring of minimal residual disease in patients with multiple myeloma. Hematology 2004;9:17-33.
32. Biondi A, Yokota S, Hansen-Hagge TE, Rossi V, Giudici G, Maglia O, et al. Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse. Leukemia 1992;6:282-8.
33. Seriu T, Hansen-Hagge TE, Erz DH, Bartram CR. Improved detection of minimal residual leukemia through modifications of polymerase chain reaction analyses based on clonospecific T cell receptor junctions. Leukemia 1995;9:316-20.
34. Szczepanski T, Willemse MJ, Brinkhof B, Van Wering ER, van der BM, van Dongen JJ. Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood 2002;99:2315-23.
35. Scrideli CA, Kashima S, Cipolloti R, Defavery R, Tone LG. Clonal evolution as the limiting factor in the detection of minimal residual disease by polymerase chain reaction in children in Brazil with acute lymphoid leukemia. J Pediatr Hematol Oncol 2002;24:364-7.
36. Merx K, Muller MC, Kreil S, Lahaye T, Paschka P, Schoch C, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α. Leukemia 2002;16:1579-83.
37. Viehmann S, Teigler-Schlegel A, Bruch J, Langebrake C, Reinhardt D, Harbott J. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement. Leukemia 2003;17:1130-6.